MiNK Therapeutics, Inc. — Director's Dealing 2022

Mar 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2022-03-09

Reporting Person: Baldoni John (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-09	Stock Option (Right to Buy)	$2.89	A	15000	Acquired	2032-03-09	Common Stock (15000)	Direct

Footnotes

F1: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.